علاج الخط الأول للتنكس المخيخي الورمي المصاحب

DOI: 10.3390/brainsci11111414

• If a patient presents with a typical clinical syndrome and specific antineuronal antibodies are detected or suspected, acute therapeutical settings aim to reduce brain inflammation and levels of circulating antibodies.
• In most cases, treatment of the underlying oncological disorder is paramount for the treatment of the paraneoplastic syndrome as well.
• Of course, choice of oncological treatment options (surgery, chemotherapy, radiotherapy) depends on tumor entity, staging, and individual aspects.
• Intravenous methylprednisolone should be chosen in a dosage of 1000 mg daily for 3–5 days.
• Courses may be repeated.
• Oral corticosteroids are mostly used as a bridging concept in case of good clinical response to first-line therapy with methylprednisolone.
• Tapering regimens beginning with a dosage of 1 mg/kg prednisolone are mostly used.